The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.
On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]
Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."
Publication
On April 17, the Office of the United States Trade Representative’s (USTR) released its Notice of Action and Proposed Action in Section 301 Investigation of China’s Targeting the Maritime, Logistics and Shipbuilding Sectors for Dominance, Request for Comments (the Notice).
Publication
The U.S. and Canada have healthcare, life science and medical device industries that are complex and interconnected.
Publication
Following publication by the European Commission of the ‘Omnibus package’ (the Omnibus) on 26 February 2025, the ‘Stop the Clock Directive’ which seeks to postpone certain dates for implementation of the EU Corporate Sustainability Directive (CSRD) and the Corporate Sustainability Due Diligence Directive (CS3D) has now come into force.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025